PharmGen Science Pre-Tax Margin
The Pre-Tax Profit Margin of PharmGen Science (004720.KS) as of Nov 2, 2026 is -87.31 %. In the previous year, Pre-Tax Profit Margin was 0.59 % — a change of -14,800.66% (lower).
Get this data via API
Financial Data API
Pre-Tax Margin
-87.31 %
YoY
-14,800.66%
Last updated:
The PharmGen Science Pre-Tax Margin history
3 Years
10 Years
25 Years
Max
| YEAR | Pre-Tax Margin | YoY |
|---|---|---|
| -87.31 % | -14,800.66% | |
| 0.59 % | -88.28% | |
| 5.07 % | -91.50% | |
| 59.60 % | +56.10% | |
| 38.18 % | +229.10% | |
| 11.60 % | +2,630.96% | |
| 0.42 % | -90.28% | |
| 4.37 % | -42.59% | |
| 7.61 % | +20.92% | |
| 6.29 % | +78.24% | |
| 3.53 % | -133.59% | |
| -10.51 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
PharmGen Science Stock analysis
Frequently Asked Questions about PharmGen Science stock
Pre-Tax Profit Margin of PharmGen Science is -87.31 % in 2025.
Pre-Tax Profit Margin of PharmGen Science changed from 0.59 % to -87.31 %, representing a -14,800.66% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin PharmGen Science since 2006 – with annual values, charts, and detailed analysis.
Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's PharmGen Science with sector peers and the industry average to assess whether it is attractive.
To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Margins — PharmGen Science
All Key Metrics — PharmGen Science
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth